おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
AlloVir
company
About
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.
- 101 - 250
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $126.60M
- Industries
- Biotechnology,Clinical Trials,Pharmaceutical
- Founded date
- Jan 1, 2013
- Number Of Employee
- 101 - 250
- Operating Status
- Active
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. It provides an ideal environment for ViraCyte to develop and advance its product pipeline from discovery through late-stage clinical trials.The company was founded in 2013 and headquartered in Houston, Texas.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$126.60M
AlloVir has raised a total of
$126.60M
in funding over 2 rounds. Their latest funding was raised on
Jul 27, 2022 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 27, 2022 | Post-IPO Equity | $126.60M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
AlloVir is funded by 1 investors.
Kite Pharma
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Kite Pharma
|
— | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
